Gaboxadol monohydrate 0.5 mg (intended commercial formulation) ( DrugBank: Gaboxadol )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
201アンジェルマン症候群1

201. アンジェルマン症候群

臨床試験数 : 24 /  薬物数 : 35 - (DrugBank : 9) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 20
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2019-004478-24-DE
(EUCTR)		05/06/202026/02/2020An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals with Angelman Syndrome (ELARA)An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals with Angelman Syndrome (ELARA) - ELARA Angelman Syndrome
MedDRA version: 20.0;Level: PT;Classification code 10049004;Term: Angelman's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: Gaboxadol monohydrate 0.5 mg (intended commercial formulation)
Product Code: OV101
INN or Proposed INN: Gaboxadol
Other descriptive name: GABOXADOL MONOHYDRATE
Product Name: Gaboxadol monohydrate 2 mg (intended commercial formulation)
Product Code: OV101
INN or Proposed INN: Gaboxadol
Other descriptive name: GABOXADOL MONOHYDRATE
Product Name: Gaboxadol monohydrate 5 mg (intended commercial formulation)
Product Code: OV101
INN or Proposed INN: Gaboxadol
Other descriptive name: GABOXADOL MONOHYDRATE		Ovid Therapeutics Inc.NULLNot RecruitingFemale: yes
Male: yes		170Phase 3United States;Australia;Israel;Netherlands;Germany